The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Open accessAbstract
Purpose: This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). Patients and Methods: Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. Stratification factors were human epidermal growth factor receptor-2 (HER2) status and geographic region. Coprimary end points were overall survival (OS) and progression-free survival (PFS). Results: Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056). Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30). Objective response rates were 11.0% for eribulin and 11.5% for capecitabine. Global health status and overall quality-of-life scores over time were similar in the treatment arms. Both treatments had manageable safety profiles consistent with their known adverse effects; most adverse events were grade 1 or 2. Conclusion: In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationJordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0345 · Cited by 489
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 483
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
Smith, J. A., Wilson, L., Azarenko, O., Zhu, X., Lewis, B. M., Littlefield, B. A., & Jordan, M. A. (2010) · Biochemistry · doi:10.1021/bi901810u · Cited by 330
Kuznetsov, G., Towle, M. J., Cheng, H., Kawamura, T., TenDyke, K., Liu, D., Kishi, Y., Yu, M. J., & Littlefield, B. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1169 · Cited by 262
Vahdat, L. T., Pruitt, B., Fabian, C. J., Rivera, R. R., Smith, D. A., Tan-Chiu, E., Wright, J., Tan, A. R., DaCosta, N. A., Chuang, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7618 · Cited by 244
Sparano, J. A., Vrdoljak, E., Rixe, O., Xu, B., Manikhas, A., Medina, C., Ventilari Da Costa, S. C., Ro, J., Rubio, G., Rondinon, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4244 · Cited by 218
Bajetta, E., Procopio, G., Celio, L., Gattinoni, L., Della Torre, S., Mariani, L., Catena, L., Ricotta, R., Longarini, R., Zilembo, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.167 · Cited by 207
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B. A., & Jordan, M. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0095 · Cited by 206
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Thadani‐Mulero, M., Nanus, D. M., & Giannakakou, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0783 · Cited by 158
Stockler, M. R., Harvey, V. J., Francis, P. A., Byrne, M., Ackland, S. P., Fitzharris, B. M., van Hazel, G., Wilcken, N. R. C., Grimison, P., Nowak, A. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9101 · Cited by 150
Goel, S., Mita, A. C., Mita, M. M., Rowinsky, E. K., Chu, Q. S.-C., Wong, N., DesJardins, C., Fang, F., Jansen, M., Shuster, D. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2429 · Cited by 145
Tan, A. R., Rubin, E. H., Walton, D. C., Shuster, D. E., Wong, Y. N., Fang, F., Ashworth, S., & Rosen, L. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0360 · Cited by 141
Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., Zheng, W., Seletsky, B. M., Zhu, X., Lewis, B. M., Kishi, Y., Yu, M. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1874 · Cited by 141
Twelves, C., Cortés, J., Vahdat, L. T., Wanders, J., Akerele, C., & Kaufman, P. A. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.023 · Cited by 108
Self-citationTreatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Moreno‐Aspitia, A., & Perez, E. A. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.6.533 · Cited by 94
Self-citationComparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
Wozniak, K. M., Nomoto, K., Lapidus, R. G., Wu, Y., Carozzi, V., Cavaletti, G., Hayakawa, K., Hosokawa, S., Towle, M. J., Littlefield, B. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4184 · Cited by 94
Synold, T. W., Morgan, R. J., Newman, E. M., Lenz, H., Gandara, D. R., Colevas, A. D., Lewis, M. D., & Doroshow, J. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3036 · Cited by 76
Andreopoulou, E., & Sparano, J. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0097-1 · Cited by 65
Yap, Y. S., Kendall, A., Walsh, G., et al. (2007) · The Breast · doi:10.1016/j.breast.2007.01.012 · Cited by 23
Cited by
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Schöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01283-0 · Cited by 778
Metadata
- Authors
- Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., & Cortes, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-02-20
- Volume
- 33
- Issue
- 6
- Pages
- 594-601
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137545466
- Cited by
- 463
- References
- 28
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.